A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development

por Bhavnani, Sujata M, Krause, Kevin M, Ambrose, Paul G
Publicado 2020

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine D...

por Lepak, Alexander J, Zhao, Miao, Vanscoy, Brian, Ambrose, Paul G, Andes, David R
Publicado 2017

Traditional PK-PD Indices for Efficacy – Can We Do Better?

por Lakota, Elizabeth A, Bader, Justin C, Bhavnani, Sujata M, Andes, David R, Ambrose, Paul G
Publicado 2017

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

por Safir, M. Courtney, Bhavnani, Sujata M., Slover, Christine M., Ambrose, Paul G., Rubino, Christopher M.
Publicado 2020

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model

por VanScoy, Brian D, Jones, Sean, Conde, Haley, Friedrich, Lawrence, Cotroneo, Nicole, Ambrose, Paul G
Publicado 2021

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects

por Van Wart, Scott A, Stevens, Christopher, Magyarics, Zoltan, Luperchio, Steven A, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1281. An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations

por VanScoy, Brian D, Conde, Haley, Cotroneo, Nicole, Critchley, Ian A, Parr, Thomas R, Ambrose, Paul G
Publicado 2021

Time for Precision: A World Without Susceptibility Breakpoints

por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado 2018

1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclon...

por Van Wart, Scott A, Tarbell, Evan D, Narayan, Kristin, Walker, Laura M, Connolly, Lynn E, Ambrose, Paul G
Publicado 2021

1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates

por Pfaller, Michael A, Flamm, Robert K, Ambrose, Paul G, Andes, David, Bradley, John S, Bhavnani, Sujata M, Jones, Ronald N
Publicado 2019

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States

por Flamm, Robert K, Pfaller, Michael A, Ambrose, Paul G, Andes, David, Bradley, John S, Bhavnani, Sujata M, Jones, Ronald N
Publicado 2019

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model

por VanScoy, Brian D, Conde, Haley, Jones, Sean, Critchley, Ian A, Parr, Thomas R, Cotroneo, Nicole, Ambrose, Paul G
Publicado 2021

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model

por VanScoy, Brian D, Conde, Haley, Vincent, Catherine E, Bhavnani, Sujata M, Aronin, Steven I, Puttagunta, Sailaja, Ambrose, Paul G
Publicado 2023

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

por Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S....

por Lepak, Alexander J, Zhao, Miao, Liu, Qingmei, Wang, Ping, Wang, Yanli, Bader, Justin C, Ambrose, Paul G, Andes, David R
Publicado 2018

Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients

por Ambrose, Paul G, Bhavnani, Sujata M, Andes, David R, Bradley, John S, Flamm, Robert K, Pogue, Jason M, Jones, Ronald N
Publicado 2020

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patien...

por Bader, Justin C, Bulik, Catharine C, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado 2017

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

por Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Publicado 2018

228. Epidemiology and Susceptibility Profiles of ST131-O25b Escherichia coli Detected Among Cephalosporin and/or Carbapenem-Resistant Isolates Collected in United States Hospitals

por Castanheira, Mariana, Castanheira, Mariana, Doyle, Timothy B, Davis, Andrew P, Kantro, Valerie, Rubino, Christopher M, Bhavnani, Sujata M, Ambrose, Paul G
Publicado 2021

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Sur...

por Bhavnani, Sujata M, Onufrak, Nikolas J, Hammel, Jeffrey P, Andes, David R, Bradley, John S, Flamm, Robert K, Ambrose, Paul G, Jones, Ronald N
Publicado 2018